Phase III clinical trials of the cell differentiation agent-2 (CDA-2): Therapeutic efficacy on breast cancer, non-small cell lung cancer and primary hepatoma1
The objective of this study was to explore the effect of CDA-2, a selective inhibitor of abnormal methylation enzymes in cancer cells, on the therapeutic efficacy of cytotoxic chemotherapy.
Advanced cancer patients, all of whom had previously undergone chemotherapy, were randomly divided into 2 groups, one receiving chemotherapy only as the control group, and the other receiving CDA-2 in addition to chemotherapy as the combination group. The therapeutic efficacies and the toxic manifestations of the 2 groups were compared based on the WHO criteria.
Of 454 cancer patients enrolled in phase III clinical trials of CDA-2, 80, 188, and 186 were breast cancer, NSCLC, and primary hepatoma patients, respectively. Among them 378 patients completed treatments according to the protocols. The results showed that the overall effective rate of the combination group was 2.6 fold that of the control group, 4.8 fold in the case of breast cancer, 2.3 fold in the case of primary hepatoma, and 2.2 fold in the case of NSCLC. Surprisingly, the combination therapy appeared to work better for stage IV than stage III patients. CDA-2 did not contribute additional toxicity. On the contrary, it reduced toxic manifestations of chemotherapy, particularly regarding white blood cells, nausea and vomiting.
Modulation of abnormal methylation enzymes by CDA-2 is definitely helpful to supplement chemotherapy. It significantly increased the therapeutic efficacy and reduced the toxic manifestation of cytotoxic chemotherapy on breast cancer and NSCLC.
Keywordsabnormal methylation enzymes DNA hypomethylation differentiation therapy adjuvant chemotherapy
Unable to display preview. Download preview PDF.
- 7.Liau MC, Lee SS, Burzynski SR. Hypomethylation of nucleic acids: a key to the induction of terminal differentiation. Intl J Exp Clin Chemother. 1989;2:187–199.Google Scholar
- 24.Liau MC. Abnormal methylation enzymes: a selective molecular target for differentiation therapy of cancer. Chin Pharm J. 2004; 56: 57–67.Google Scholar
- 31.Liau MC, Luong Y, Liau CP, et al. Prevention of drug induced DNA hypermethylation by antineoplaston components. Intl J Exp Clin Chemother. 1992;5:19–27.Google Scholar
- 32.Liau MC, Lee SS, Burzynski SR. Modulation of cancer methylation complex isozymes as a decisive factor in the induction of terminal differentiation mediated by Antineoplaston A5. Intl J Tiss React 1990;12(Suppl.l):27–36.Google Scholar
- 33.Liau MC, Huang LJ, Lee JH, et al. Development of differentiation helper inducers for the differentiation therapy of cancer. Chin Pharm J. 1998;50:289–303.Google Scholar
- 34.Liau MC, Liau CP. Methyltransferase inhibitors as excellent differentiation helper inducers for differentiation therapy of cancer. Bull Chin Cancer. 2002;11:166–168.Google Scholar
- 35.Liau MC, Szopa M, Burzynski B, et al. Chemo-surveillance: a novel concept of natural defense mechanism against cancer. Drugs Exp Clin Res. 1987;13:(Suppl.l): 77–82.Google Scholar
- 36.Liu YK, Li Y, Ma X, et al. Regulation of liver cancer related genes and alpha fetal protein expression by CDA -2. Bull Chin Cancer. 2002;11:169–172.Google Scholar
- 37.Sun JJ, Zhou XD, Liu YK, et al. Prevention of metastasis and recurrence in xenografted nude mice by differentiation inducer CDA-2. Chin Hepatobill J. 1999;5:14–16.Google Scholar
- 38.Xu JY, Zhou Q, Lu P, et al. Induction of apoptosis and reversal of drug resistance in human tumor cell line KBv200 by cell differentiation agent-2 (CDA-2). Chin J Intern Med. 2000;39:37–39.Google Scholar
- 39.Liao SK. Abrogation of telomerese activity by CDA-2. In: Liau MC. Smart Anticancer Drug CDA-2. Taipei, Taiwan: Shymou Publishing Co. 1999;188–190.Google Scholar
- 40.Meng ZQ, Huang, WX, Wang ZJ. Phase II clinical trial of CDA-2 on breast cancer. Bull Chin Cancer. 2002;11:113–114.Google Scholar
- 41.Gao YT, Shi SQ, Gu FL, et al. The effect of CDA -2 on advanced liver cancer in 15 cases. Bull Chin Cancer. 2002; 11:110–112.Google Scholar
- 42.Feng FY, Li Q, Wang ZJ. Effect of uroacitides in improving quality of life of advanced cancer patients. Chin J Clin Rehab. 2004;8:384–385.Google Scholar
- 43.Chen ZS, Ni M, Cheng HH, et al. Therapeutic efficacy of CDA-2 on advanced cancer patients: a comparison with cytotoxic chemotherapy. Chin J Clin Oncol Rehab. 1999;6:84–87.Google Scholar
- 44.Lai TY, Wu YW, Lin WC. Effect of an urinary preparation on acute liver injury induced by carbon tetrachloride. Chin Pharm J. 1998; 50:175–187.Google Scholar